PUBLICATION

The single nucleotide variant at c.662A>G in human RRM2B is a loss-of-function mutation

Authors
Tseng, Y.T., Li, S.W., HuangFu, W.C., Yen, Y., Liu, I.H.
ID
ZDB-PUB-201002-63
Date
2020
Source
Molecular genetics & genomic medicine   8(11): e1497 (Journal)
Registered Authors
Tseng, Yen-Tzu
Keywords
none
MeSH Terms
  • Animals
  • Cell Cycle Proteins/genetics*
  • Cell Cycle Proteins/metabolism
  • Humans
  • Loss of Function Mutation*
  • Mitochondrial Diseases/genetics*
  • Muscular Dystrophies/genetics*
  • Point Mutation
  • Ribonucleotide Reductases/genetics*
  • Ribonucleotide Reductases/metabolism
  • Zebrafish
PubMed
32931159 Full text @ Mol Genet Genomic Med
Abstract
Mitochondrial DNA maintenance defects (MDMDs) is one of the critical pediatric dysfunction. One of the recent report indicated that a severe patient of MDMDs carries the NP_056528.2:p.Asn221Ser (N221S) variation in the RRM2B gene (NM_015713.5). However, there is no direct evidence demonstrating the nature of the N221S variation.
This study aimed to utilize zebrafish and morpholino oligomer (MO) knockdown technique to provide direct evidence for the nature of the N221S variation in the RRM2B.
The results showed that two distinct MOs were both able to perturb the expression of rrm2b in zebrafish and dose-dependently induced morphological defects. Furthermore, co-injection of human wild-type RRM2B mRNA with MO-e4i4 successfully rescued the developmental defects, whereas co-injection of RRM2B/N221S mRNA with MO-e4i4 did not rescue the developmental defects.
In conclusion, the functional assay in this study provided the direct evidence proving that the N221S variation is a loss-of-function mutation and plausibly related to the pathogenic developmental defects found in the infants of previous clinical reports.
Genes / Markers
Figures
Show all Figures
Expression
Phenotype
Mutation and Transgenics
Human Disease / Model Data
Sequence Targeting Reagents
Fish
Antibodies
Orthology
Engineered Foreign Genes
Mapping
Errata and Notes